Historical Valuation
Bio-Techne Corp (TECH) is now in the Fair zone, suggesting that its current forward PE ratio of 29.51 is considered Fairly compared with the five-year average of 41.74. The fair price of Bio-Techne Corp (TECH) is between 65.48 to 104.43 according to relative valuation methord.
Relative Value
Fair Zone
65.48-104.43
Current Price：66.24
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bio-Techne Corp (TECH) has a current Price-to-Book (P/B) ratio of 4.73. Compared to its 3-year average P/B ratio of 5.48 , the current P/B ratio is approximately -13.68% higher. Relative to its 5-year average P/B ratio of 7.15, the current P/B ratio is about -33.91% higher. Bio-Techne Corp (TECH) has a Forward Free Cash Flow (FCF) yield of approximately 2.41%. Compared to its 3-year average FCF yield of 2.22%, the current FCF yield is approximately 8.50% lower. Relative to its 5-year average FCF yield of 2.05% , the current FCF yield is about 17.66% lower.
P/B
Median3y
5.48
Median5y
7.15
FCF Yield
Median3y
2.22
Median5y
2.05
Competitors Valuation Multiple
AI Analysis for TECH
The average P/S ratio for TECH competitors is 167.36, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH.O) exhibits a P/S ratio of 7.51, which is -95.51% above the industry average. Given its robust revenue growth of -1.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TECH
1Y
3Y
5Y
Market capitalization of TECH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TECH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TECH currently overvalued or undervalued?
Bio-Techne Corp (TECH) is now in the Fair zone, suggesting that its current forward PE ratio of 29.51 is considered Fairly compared with the five-year average of 41.74. The fair price of Bio-Techne Corp (TECH) is between 65.48 to 104.43 according to relative valuation methord.
What is Bio-Techne Corp (TECH) fair value?
TECH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bio-Techne Corp (TECH) is between 65.48 to 104.43 according to relative valuation methord.
How does TECH's valuation metrics compare to the industry average?
The average P/S ratio for TECH's competitors is 167.36, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH) exhibits a P/S ratio of 7.51, which is -95.51% above the industry average. Given its robust revenue growth of -1.00%, this premium appears unsustainable.
What is the current P/B ratio for Bio-Techne Corp (TECH) as of Jan 10 2026?
As of Jan 10 2026, Bio-Techne Corp (TECH) has a P/B ratio of 4.73. This indicates that the market values TECH at 4.73 times its book value.
What is the current FCF Yield for Bio-Techne Corp (TECH) as of Jan 10 2026?
As of Jan 10 2026, Bio-Techne Corp (TECH) has a FCF Yield of 2.41%. This means that for every dollar of Bio-Techne Corp’s market capitalization, the company generates 2.41 cents in free cash flow.
What is the current Forward P/E ratio for Bio-Techne Corp (TECH) as of Jan 10 2026?
As of Jan 10 2026, Bio-Techne Corp (TECH) has a Forward P/E ratio of 29.51. This means the market is willing to pay $29.51 for every dollar of Bio-Techne Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bio-Techne Corp (TECH) as of Jan 10 2026?
As of Jan 10 2026, Bio-Techne Corp (TECH) has a Forward P/S ratio of 7.51. This means the market is valuing TECH at $7.51 for every dollar of expected revenue over the next 12 months.